Led the launch planning and execution of two inflammation assets & managed a third asset. During this time, I led and developed a team of three (3), while also leading the crossfucntioanl team; successfully led various teams through unprecedented market conditions and commercialization model evolution.

Led workstreams to shape positioning of inflammation portfolio to maximize value across assets and indications; portfolio delivered $6B in highly competitive markets

Owned all aspects of brand planning (strategy, tactics, resource optimization, forecasting), and performance evaluation (QBRs, KPIs) for Enbrel ($5B brand).

Developed and executed promotional plans that resulted in 10% YoY growth (2018 - 2020) for Nplate. During my time on the brand, I led efforts to re-launch the brand, and led the strategy and execution for launches of two indications and a new field salesforce, while also defending our position against two new entrants to the market.

Owned Patient and HCP NPP marketing strategy and execution. Managed and executed a multi-million-dollar budget, delivering a 6:1 ROI across HCP NPP and Consumer for Nplate. Enhanced performance of media placements and expanded digital presence into new channels for both HCP and Consumer

Supported IMLYGIC (oncolytic virus therapy for melanoma) Ex-US launch efforts by developing a variety of access tools including – access toolkit, comparator primers, in-country regional payer evaluation assessments, objection handlers & engaging with regional and affiliate leads for pull-through

• Established relationships with key stakeholders in various accounts to support sales activities for various oncology products including Xgeva®, Prolia®, Nplate®, Neupogen®, Neulasta® and the Neulasta® On-body injector - annual sales total ~ $12.0M • Collaborated with team members to devise strategy for launch of the Neulasta® On-body injector, introduce the product to various customers, and support activities for device use. • Supported launch efforts for the Hypercalcemia of Malignancy indication of Xgeva®• Initiated project to analyze emerging trends in oncology care and identify the impact and opportunities for the company; successfully presented findings to the region

• Analyzed partnership structures between large biotech/pharma and early stage companies that align with company's short and long term development objectives• Developed presentation materials for $60M series D financing round due diligence meeting• Conducted market sizing analysis of several markets - U.S., EU5, Japan - for lead candidate PNT2258, and two potential early stage assets. Results of analysis were used to determine company's valuation• Conducted mode of action research for lead drug candidate• Identified over 300 additional DNA targets for future DNAi technology development consideration• Developed preliminary screening tool for future DNA target prioritization

• Developed market entry model for simulating contracting scenarios of new Brandedand Biosimilar products• Assessed potential impact of new competitor to Amgen legacy product.  Results wereused to verify Amgenʹs contracting strategy

• Conducted Competitive Analysis to create marketing tools for sales team to introduce PharmaSecure products to eight prospective customers• Led effort to implement CRM system to improve communications among sales team located in India and the U.K., and staff in the U.S.• Analyzed current and potential clients to develop a financial model quantifying potential losses from drug-counterfeit for 10+ top‑selling pharmaceutical brands• Awarded 2012 WDI-PharmaSecure Global Impact Internship and Fellowship

• Led investigation into use of components for clinical delivery of Kadcyla™; identified alternative components for safe delivery of drug which were later adopted in the clinic • Developed database for qualification of clinical components used by clinical sites world-wide; resulted in 30% reduction of time needed to qualify components• Designed and executed studies in support of formulation activities for the commercial launch of Kadcyla™; received award for individual contributions to project

• Designed and executed studies to support clinical use of two late-stage drugs; the data generated was used to support multiple regulatory filings in the U.S. and Europe